SCHEMBL2989004

SCHEMBL2989004

Clc1ccc(-c2ccnc(-c3cccc(-c4ccccc4)n3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRC Q99895 1/20 0.50
MAP4K4 O95819 1/20 0.50
PIM1 P11309 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
RAB9A P51151 1/20 0.48
TGFBR1 P36897 1/20 0.47
CNR1 P21554 2/20 0.46
CYP1A2 P05177 1/20 0.46
SMO Q99835 2/20 0.45
GRM5 P41594 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
KMO O15229 1/20 0.44
MAPK13 O15264 1/20 0.44
GCGR P47871 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
HTT P42858 1/20 0.44
CCR1 P32246 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258633 0.89 CCR1 (0.57) MAP4K4RAB9ATGFBR1CNR1CYP1A2
SCHEMBL23487646 0.87 MAP4K4 (0.62) CTRCMAP4K4PIM1RAB9ATGFBR1
SCHEMBL18603218 0.87 MAP4K4 (0.62) CTRCMAP4K4PIM1RAB9ATGFBR1
SCHEMBL30501156 0.87 MAP4K4 (0.62) CTRCMAP4K4PIM1RAB9ATGFBR1
SCHEMBL2994631 0.85 ALDH1A1 (0.58) MEN1KMT2ARAB9ASMOALDH1A1
SCHEMBL23598407 0.83 MEN1 (0.53) PIM1MEN1KMT2ARAB9ATGFBR1
SCHEMBL1991845 0.82 KDM4E (0.64) MEN1KMT2ARAB9ATGFBR1CYP1A2
SCHEMBL28598181 0.82 RAB9A (0.73) CTRCMEN1KMT2ARAB9ACNR1
SCHEMBL16242324 0.82 MAP4K4 (0.62) MAP4K4PIM1MEN1KMT2ATGFBR1
SCHEMBL15024091 0.80 KDM4E (0.67) MEN1KMT2ARAB9ATGFBR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357800-B2 Bipyridine metal complexes for use as light-emitting material SOLVAY (SOCIETE ANONYME) (BE) 2013-01-22 US disclosed
US-20100174078-A1 Bipyridine metal complexes for use as light-emitting material SOLVAY (SOCIETE ANONYME) (BE) 2010-07-08 US disclosed
EP-2155765-A1 BIPYRIDINE METAL COMPLEXES FOR USE AS LIGHT-EMITTING MATERIAL SOLVAY (BE) 2010-02-24 EP disclosed
WO-2008148830-A1 BIPYRIDINE METAL COMPLEXES FOR USE AS LIGHT-EMITTING MATERIAL SOLVAY (BE) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174078-A1 Bipyridine metal complexes for use as light-emitting material OCIAD2, AP2M1, OCIAD1 CTRC 2978/4885MAP4K4 2690/4885PIM1 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.